nature research

Corresponding author(s):

Double-blind peer review submissions: write DBPR and your manuscript number here

instead of author names.

Last updated by author(s): YYYY-MM-DD

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

<u> </u>				
S 1	· a:	tic	11	\sim

FOI a	ii StatiSticai ari	alyses, commit that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a	Confirmed			
	The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement		
	X A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
	The statist Only comm	tical test(s) used AND whether they are one- or two-sided on tests should be described solely by name; describe more complex techniques in the Methods section.		
	🔀 A descript	ion of all covariates tested		
	🔀 A descript	ion of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
		cription of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) tion (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
	For null hy Give P value	pothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted as as exact values whenever suitable.		
\boxtimes	For Bayesi	ian analysis, information on the choice of priors and Markov chain Monte Carlo settings		
\boxtimes	For hierar	chical and complex designs, identification of the appropriate level for tests and full reporting of outcomes		
\boxtimes	\boxtimes Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated			
·		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.		
Software and code				
Policy information about <u>availability of computer code</u>				
Dat	a collection	No software was used to collect data.		

Data analysis

 $TOIL\ v3.3.4,\ Molecular\ Signatures\ Database\ (MSigDB)\ v7.0,\ GSEA/MSigDB\ web\ site\ v6.4,\ python\ v3.6.8,\ pandas\ v0.25.3,\ matplotlib\ v3.0.3,\ seaborn\ v0.9.0,\ sklearn\ v0.22.1,\ scanpy\ v1.6.7$

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The TCGA and CCLE processed gene expression data are publicly available at UCSC Xena (xena.ucsc.edu). The processed micro-RNA sequencing data are publicly available at the Genomic Data Commons and the Broad Institute CCLE database (portals.broadinstitute.org/ccle/data). The protein quantification data are publicly available at the The Cancer Proteome Atlas (TCPA) portal (tcpaportal.org/tcpa/download.html and tcpaportal.org/mclp/#/download). The mutation data are publicly available at UCSC Xena and the Broad Institute CCLE database. The hepatocellular carcinoma single cell RNA sequencing data are publicly available at the following accessions: GSE103867 and GSE112271. The brain tumor single cell RNA sequencing data are publicly available at the following accession: GSE213519.

Field-specific reporting					
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.					
\times Life sciences \qquad \qqqqq\qqqq\qqqq\qqqq\qqqq\qqqq\qqqq\					
For a reference copy of t	he document with all sections, see <u>nature.</u>	com/documents/nr-reporting-summary-flat.pdf			
Life scier	nces study desig	gn			
All studies must disclose on these points even when the disclosure is negative.					
Sample size	Sample sizes were determined by availability of data.				
Data exclusions	The only data exclusions were samp	es from tumor types which did not overlap between the TCGA and CCLE cohorts.			
Replication	Statistical gene selection using a sup	port vector machine was performed in 50 independent experiments with random 80/20 sample splits in			
Randomization	Samples were allocated into experimental groups on the basis of sample type (tumor, cell line).				
Blinding	Blinding is not relevant to our study since all covariates must be known for the comparative analyses.				
Reporting for specific materials, systems and methods					
		materials, experimental systems and methods used in many studies. Here, indicate whether each material, enot sure if a list item applies to your research, read the appropriate section before selecting a response.			
Materials & experimental systems Methods		Methods			
n/a Involved in the study		n/a Involved in the study			
Antibodies		ChIP-seq			

Flow cytometry

MRI-based neuroimaging

Eukaryotic cell lines

Clinical data

 \boxtimes

 \boxtimes

Palaeontology and archaeology

Animals and other organisms

Human research participants

Dual use research of concern